EUCTR2009-010587-42-GR进行中（未招募）1 期
A Randomized Open-Label Study to Evaluate the Safety and Efficacy of Denosumab and Monthly Actonel® Therapies in Postmenopausal Women Transitioned from Weekly or Daily Alendronate Therapy.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Amgen Inc
- 入组人数
- 800
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Subjects will meet the following inclusion criteria prior to enrolment:
- •- Ambulatory, postmenopausal women (based on medical history) aged 55 years or older at screening:
- •Postmenopause will be defined as no vaginal bleeding or spotting for at least 12 months
- •If the subject is < 60 years old and there is uncertainty regarding menopausal status, confirmation of serum FSH (= 50 mIU/mL) and serum estradiol (= 20 pg/mL) must be obtained
- •- Have received their first prescription of daily or weekly bisphosphonate therapy,
- •as the initial treatment for post menopausal osteoporosis in the 18 months prior to
- •screening. Use of raloxifene, calcitonin prior to alendronate treatment will be allowed. Prior and current use of vitamin D and calcium will be allowed.
- •Hormone replacement therapy (e.g. estrogen use for mitigation of
- •menopausal symptoms) will be allowed.
- •- Subject has demonstrated 1 of the following:
- •Has stopped oral alendronate therapy (is denoted as non-persistent) at least one month before the screening visit
- •Is still taking oral alendronate therapy but demonstrates low adherence to therapy assessed by a score of less than 6 on the Osteoporosis Specific Morisky Medication Adherence Scale (OS-MMAS)
- •- Provide signed informed consent before any study-specific procedures are conducted
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects meeting any of the following criteria are not eligible for participation in the study:
- •- Any prior or current use of medications prescribed for osteoporosis treatment other than:
- •oral daily or weekly alendronate
- •Hormone replacement therapy (e.g. estrogen use to mitigate
- •menopausal symptoms)
- •calcium and vitamin D
- •prior use of raloxifene and calcitonin before alendronate therapy was initiated will
- •be allowed. Use of these therapies must have stopped prior to initiating oral
- •alendronate and their current use is not allowed
- •- Hypersensitivity to Actonel® or other constituents of Actonel® tablets
- •- Contraindicated or poorly tolerant of alendronate therapy; contraindications for alendronate therapy include:
- •Abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia
- •Inability to stand or sit upright for at least 30 minutes
- •- Active gastric or duodenal ulcer; history of significant gastrointestinal bleed requiring hospitalization or transfusion, or dyspepsia or gastro esophageal reflux disease that is uncontrolled by medication
- •- Known sensitivity to mammalian cell derived drug products
- •- Known intolerance to calcium supplements
- •- Malignancy within the last 5 years (except cervical carcinoma in situ or basal cell carcinoma
- •- Vitamin D deficiency [25(OH) vitamin D level < 20 ng/mL (< 49.9 nmol/L)] - Repletion will be allowed and subjects may be re-screened
- •- Current hypo- or hypercalcemia based on the central laboratory reference ranges
- •- Uncontrolled hyper- or hypothyroidism (stable on antithyroid therapy or post-ablation is allowed, if the central laboratory TSH is within the normal range)
- •- Hyper- or hypoparathyroidism per the central laboratory reference ranges
- •- Any metabolic bone disease, eg, osteomalacia or osteogenesis imperfecta, Paget’s
- •disease of bone, that may interfere with the interpretation of the findings, and other
- •disorders including
- •Significantly impaired renal function as determined by a derived glomerular
- •filtration rate (GFR) (using the Modification of Diet in Renal Disease [MDRD]
- •formula) of = 30 mL/min/1.73 m2 calculated by the central laboratory.
- •Clinically determined malabsorption syndrome that may result from disorders such as celiac disease, gastric bypass surgery, bowel
- •resection, uncontrolled diarrhea and steatorrhea.
- •Elevated transaminases = 2.0 x upper limits of normal (ULN)
- •- Height, weight or girth which may preclude accurate DXA measurements
- •- Fewer than 2 lumbar vertebrae (L1-L4) able to be evaluated by DXA
- •- Known to have tested positive for human immunodeficiency virus
- •- Previous participation in clinical trials with denosumab within the last 12 months (regardless of treatment)
- •- Any laboratory abnormality, physical or psychiatric disorder (including substance abuse in last 12 months) which, in the opinion of the investigator, will prevent the subject from giving written informed consent or completing the study or interfere with the interpretation of the study results
- •- Currently enrolled in or within 30 days of ending another investigational device or drug trial(s)
- •- Administration of any of the following treatments within 3 months of screening
- •Anabolic steroids or testosterone
- •Glucocorticosteroids (= 5 mg prednisone equivalent per day for more than 10
- •days or a total cumulative dose of = 50 mg)
研究者
相似试验
进行中（未招募）
不适用
A Randomized Open-Label Study to Evaluate the Safety and Efficacy of Denosumab and Monthly Actonel® Therapies in Postmenopausal Women Transitioned from Weekly or Daily Alendronate Therapy./ Estudio abierto y aleatorizado para evaluar la seguridad y eficacia del tratamiento con denosumab y con Actonel® mensual en mujeres posmenopáusicas tras la transición del tratamiento con alendronato semanal o diario.Postmenopausal osteoporosis / Osteoporosis posmenopáusicaMedDRA version: 9.1Level: LLTClassification code 10031285Term: Osteoporosis postmenopausalEUCTR2009-010587-42-ESAmgen Inc800
进行中（未招募）
不适用
Study to Evaluate the Safety and Efficacy of Denosumab and Actonel® in Post Menopausal Women Transitioned From Alendronate TherapyPostmenopausal osteoporosisMedDRA version: 14.0Level: PTClassification code 10031285Term: Osteoporosis postmenopausalSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2009-010587-42-ATAmgen Inc800
进行中（未招募）
不适用
A Randomized Open-Label Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated with Daily or Weekly Bisphosphonates./ Estudio abierto aleatorizado para evaluar la seguridad y eficacia de denosumab e ibandronato en mujeres posmenopáusicas infratratadas con bisfosfonatos diarios o semanales.Postmenopausal osteoporosis / Osteoporosis posmenopáusicaMedDRA version: 9.1Level: LLTClassification code 10031285Term: Osteoporosis postmenopausalEUCTR2009-010726-19-ESAmgen Inc800
进行中（未招募）
不适用
A Randomized Open-Label Study to Evaluate the Safety and Efficacy of Denosumab and Monthly Actonel Therapies in Postmenopausal Women Transitioned from Weekly or Daily Alendronate Therapy. - Denosumab 20080099Post menopausal osteoporosisMedDRA version: 12.0Level: LLTClassification code 10031285Term: Osteoporosis postmenopausalEUCTR2009-010587-42-ITAmgen Inc800
进行中（未招募）
不适用
Study to Evaluate the Safety and Efficacy of Denosumab and Actonel® in Post Menopausal Women Transitioned From Alendronate TherapyMedDRA version: 14.0Level: PTClassification code 10031285Term: Osteoporosis postmenopausalSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersPostmenopausal osteoporosisEUCTR2009-010587-42-DEAmgen Inc800